MX2018015363A - Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria. - Google Patents

Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.

Info

Publication number
MX2018015363A
MX2018015363A MX2018015363A MX2018015363A MX2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A
Authority
MX
Mexico
Prior art keywords
celiac
celiac disease
treatment
methods
refractory
Prior art date
Application number
MX2018015363A
Other languages
English (en)
Spanish (es)
Inventor
Leon Francisco
H Tsuji Wayne
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2018015363A publication Critical patent/MX2018015363A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2018015363A 2016-06-15 2016-06-15 Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria. MX2018015363A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/037708 WO2017217985A1 (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Publications (1)

Publication Number Publication Date
MX2018015363A true MX2018015363A (es) 2019-04-15

Family

ID=56292925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015363A MX2018015363A (es) 2016-06-15 2016-06-15 Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.

Country Status (11)

Country Link
EP (1) EP3472202A1 (zh)
JP (2) JP2019521981A (zh)
CN (1) CN109311972A (zh)
AR (1) AR108790A1 (zh)
AU (1) AU2016411388A1 (zh)
BR (1) BR112018076287A2 (zh)
CA (1) CA3020894A1 (zh)
EA (1) EA201892707A1 (zh)
MX (1) MX2018015363A (zh)
TW (2) TW201803591A (zh)
WO (1) WO2017217985A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558369A4 (en) 2016-12-21 2020-09-09 Cephalon, Inc. ANTIBODIES SPECIFICALLY BINDING TO HUMAN IL-15 AND THEIR USES
JP2022512709A (ja) * 2018-10-31 2022-02-07 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
IL310275A (en) 2021-08-12 2024-03-01 Amgen Inc Antibody formulations
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EA015897B1 (ru) * 2003-02-26 2011-12-30 Генмаб А/С Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие
UA102722C2 (en) * 2009-01-29 2013-08-12 Эббви Инк. Il-1 binding proteins
WO2011031986A1 (en) * 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15

Also Published As

Publication number Publication date
AU2016411388A1 (en) 2018-11-08
EP3472202A1 (en) 2019-04-24
CN109311972A (zh) 2019-02-05
BR112018076287A2 (pt) 2019-03-26
JP2022001577A (ja) 2022-01-06
TW202327653A (zh) 2023-07-16
EA201892707A1 (ru) 2019-05-31
TW201803591A (zh) 2018-02-01
AR108790A1 (es) 2018-09-26
WO2017217985A1 (en) 2017-12-21
CA3020894A1 (en) 2017-12-21
JP2019521981A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
MD20170032A2 (ro) Anticorpi anti-TIGIT
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
NZ737399A (en) Ccr2 modulators
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2017002489A (es) Agentes terapeuticos humanos.
PH12018502154A1 (en) Methods of treating ocular conditions
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PH12017500602A1 (en) Methods for treating ocular conditions
MX2018015363A (es) Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
EA201791937A1 (ru) Противовоспалительные полипептиды
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
WO2018211324A8 (en) Prodrugs for the treatment of disease
PH12017501979A1 (en) Pharmaceutical compound